One of those mysteries: why the experience can be so very different from one person to another. One expert says the answer could mean a closer look at previous vaccines individuals have had.
“When we looked at the setting of Covid disease, we found that people who had previous vaccinations with a variety of vaccines – for pneumococcus, influenza, hepatitis and others – seemed to have a lower risk of getting Covid disease,” said Dr. Andrew Badley, an infectious disease specialist at the Mayo Clinic, told CNN Anderson Cooper on Monday night.
What immunologists call immune training: how your immune system creates an effective response to fight infections, says Badley.
“A good analogy is to think of your immune system as a muscle,”; he said. “The more you exercise that muscle, the stronger it will be when you need it.”
But once you are infected, how much of the virus made it into your body can also affect what your experience is, another expert told CNN on Monday.
The Gandhi team that found the masks makes a difference.
“What makes the mask really is the reduction in the amount of virus you get, if you get infected,” she said. “And by reducing it … you have a lower dose, you are able to manage it, you are able to have a calm response and you have mild symptoms or no symptoms at all.”
To date, more than five million Americans have tested positive for the virus and at least 163,461 have died.
90% increase in cases of children in one month
More research is also emerging about children and coronavirus in the middle of the school season.
According to a report published Monday by the American Academy of Pediatrics and the Children’s Hospital Association, there has been a 90% increase in the number of coronavirus cases among children in the US over four weeks.
The new report, which is expected to be updated weekly, said there were 179,990 new Covid-19 cases among American children between July 9 and August 6.
More than 380,000 children had been infected since August 6th, according to the report, accounting for just over 9% of total cases in states reporting cases by age.
And while some U.S. officials, including the President, have said the virus does not pose a major risk to children, experts say it does not.
“It is not fair to say that this virus is completely benign in children,” said Dr. Sean O’Leary, vice chair of the American Pediatric Committee on Infectious Diseases. “We have had 90 child deaths in the US already, in just a few months. Wedo year we worry about the flu in children, and there are approximately 100 child deaths from the flu each year.”
In Mississippi, at least 22 schools across the state have reported positive cases, said State Director of Health Dr. Thomas Dobbs during a press conference this week. There were 19 reported cases among students and 15 cases among staff.
More volunteers were added to the antibody therapy trials
Meanwhile, two clinical trials of late-stage antibody therapy are enrolling more volunteers through the National Allergy Institute and the Covid-19 Infectious Disease Prevention Network (CoVPN), giving the studies a wider range of sites and a larger group of people.
These therapies are laboratory-made antibodies to target a specific infection or toxin. If they work, treatments can provide protection against the virus immediately, as opposed to a vaccine, which can take several weeks before it starts to provide protection and may not provide protection after someone is already infected. But antibody therapies usually only work for a couple of months, while vaccines offer long-term protection.
In the first trial, volunteers are given a placebo or a dose of REGN-COV-2, an antibody treatment made by Regeneron Pharmaceuticals, which has shown success in laboratory and animal studies and has been shown to be safe in human trials.
The trial will try to see if the antibody cocktail provides protection against the disease and if someone is infected, if the treatment limits the number of symptoms and if it helps to keep people out of the hospital.
Scientists hope to record 2,000 asymptomatic adults who have had contact with someone in their family who has an infection. Volunteers will receive the treatment within a 96-hour window after coming into contact with the infected person, and scientists will check with them again for seven months to ensure the treatment was safe and effective.
The second trial will test to see how Eli Lilly and Company LY-CoV555 antibody treatment works with people working or living in a nursing home or assisted living institution who have had a positive case.
That trial, seeking 2,400 volunteers, will test whether therapy prevents infections in this vulnerable population and will also test whether therapy prevents symptoms or reduces the severity of the disease.
CNN’s Jen Christensen and Jamiel Lynch contributed to this report.